Andrea Alimonti

MD
Molecular Oncology
Oncology Institute of Southern Switzerland
Switzerland

Academician Biomedical Sciences
Biography

My research is focused on the characterization of a novel type of cellular senescence response which is elicited by complete loss of the tumor suppressor PTEN, and on the identification of novel compounds with pro-senescence activity. My final aim is to develop the concept of pro-senescence therapy for cancer, from experimental evidences to clinic, investigating the efficacy of “pro-senescence” compounds in phase I clinical trials. This will also allow for the identification of senescence markers in human tumor samples to be used in clinic. Biography 2007– 2009 BIDMC - Harvard Medical School (Boston, USA), Pandolfi Laboratory, Postdoctoral Clinical/Research Fellow. 2004–2007 Memorial Sloan-Kettering Cancer Center (New York, USA), Pandolfi Laboratory, Postdoctoral Clinical/Research Fellow. 2000– 2004 Regina Elena National Cancer Institute (Rome, Italy), Resident in Clinical Oncology. 2000 MD degree, University of Rome ”La Sapienza” (Italy).

Research Intrest

characterization of a novel type of cellular senescence, tumor suppressor PTEN, therapy for cancer

List of Publications
Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer treatment reviews. 2004 Oct 31;30(6):555-62.
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. The Journal of clinical investigation. 2010 Mar 1;120(3):681.
Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL. Subtle variations in Pten dose determine cancer susceptibility. Nature genetics. 2010 May 1;42(5):454-8.